Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer
Alexa B. Schrock(Foundation Medicine (United States)), Ching Ouyang(City Of Hope National Medical Center), Jaideep Sandhu(City of Hope), Ethan S. Sokol(Foundation Medicine (United States)), Dexter X. Jin(Foundation Medicine (United States)), Jeffrey S. Ross(SUNY Upstate Medical University), V.A. Miller(Foundation Medicine (United States)), Dean Lim(City of Hope), Idoroenyi Amanam(City of Hope), Joseph Chao(City of Hope), Daniel V.T. Catenacci(University of Chicago Medical Center), M. Cho(UC Davis Comprehensive Cancer Center), Fadi Braiteh(Comprehensive Cancer Centers of Nevada), Samuel J. Klempner(Angeles Clinic and Research Institute), Siraj M. Ali(Foundation Medicine (United States)), Marwan Fakih(City of Hope)
Cited by 625